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ABSTRACT
In patients with ESRD, residual kidney function (RKF) contributes to achievement of adequate solute
clearance. However, few studies have examined RKF in patients on hemodialysis. In a longitudinal cohort of
6538 patients who started maintenance hemodialysis over a 4-year period (January 2007 through December
2010) and had available renal urea clearance (CLurea) data at baseline and 1 year after hemodialysis initiation,
we examined the association of annual change in renal CLurea rate with subsequent survival. The median
(interquartile range) baseline value and mean6SD annual change of CLurea were 3.3 (1.9–5.0) and 21.162.8
ml/minper 1.73m2, respectively.GreaterCLurea rate1 year after hemodialysis initiationassociatedwithbetter
survival. Furthermore,we foundagradient associationbetween lossofRKFandall-causemortality: changes in
CLurea rateof26.0 and+3.0ml/minper 1.73m
2per year associatedwith casemix–adjustedhazard ratios (95%
conﬁdence intervals) of 2.00 (1.55 to 2.59) and 0. 61 (0.50 to 0.74), respectively (reference: 21.5 ml/min per
1.73 m2 per year). These associations remained robust against adjustment for laboratory variables and ultra-
ﬁltration rate andwere consistent across strata of baseline CLurea, age, sex, race, diabetes status, presence of
congestive heart failure, and hemoglobin, serum albumin, and serum phosphorus levels. Sensitivity analyses
using urine volume as another index of RKF yielded consistent associations. In conclusion, RKF decline during
the ﬁrst year of dialysis has a graded association with all-cause mortality among incident hemodialysis pa-
tients. The clinical beneﬁts of RKF preservation strategies on mortality should be determined.
J Am Soc Nephrol 27: 3758–3768, 2016. doi: 10.1681/ASN.2015101142
In patients with ESRD, residual kidney function
(RKF) contributes to achievement of adequate sol-
ute clearance and is associated with health and pa-
tient survival.1,2 RKF, even at such low levels as in
patients undergoing maintenance dialysis, substan-
tially contributes to solute clearance, particularly
for protein-bound solutes and middle mole-
cules,3,4 and among patients undergoing peritoneal
dialysis, it has been shown that residual renal clear-
ance is more strongly associated with survival ver-
sus dialysis clearance.5–8 Although this may also be
the case in patients on hemodialysis, there is pau-
city of such data. Other beneﬁts conferred by RKF
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include better ﬂuid andmetabolic homeostasis, less severity of
mineral and bone abnormalities, and greater endogenous
production of erythropoietin and calcitriol.7–12 These factors
allow for greater ﬂuid and dietary liberalization in this pop-
ulation and may prevent common complications in patients
with ESRD, such as left ventricular hypertrophy, arterial me-
dia calciﬁcation, and congestive heart failure.
The importance of RKF in patients on peritoneal dialysis is
widely known, but only a few studies have examined RKF in pa-
tients on hemodialysis, despite the fact that up to 45% of patients
in the United States initiate maintenance dialysis at eGFRs.10
ml/min per 1.73 m2.13,14 Paucity of prior study in this area
may, in part, be because of misconceptions that RKF declines
rapidly after starting maintenance hemodialysis, when, in fact,
the rates of RKF decline in patients on hemodialysis may be
similar to those in patients on peritoneal dialysis if the current
standard biocompatible membranes and bicarbonate buffer
are used.15–17 In addition, timed urine collections for patients
undergoing maintenance hemodialysis are labor intensive, and
hence, they are not performed routinely. This is likely another
important reason for the paucity of studies of RKF in patients
on hemodialysis.
To address this knowledge gap, we studied a large national
cohort of incident hemodialysis patients in the United States
for 5 years to determine which clinical factors at the time of
initiation of hemodialysis predict preserved RKF at 1 year and
quantitatively investigate the association of annual change in
RKFwith survival.Wehypothesized that faster decline inRKF
has a dose-dependent association with higher mortality,
irrespective of baseline RKF or comorbid conditions, in
incident hemodialysis patients.
RESULTS
Baseline Demographic, Clinical, and Laboratory
Characteristics
Compared with the 44,416 excluded patients who lacked
baseline residual renal urea clearance (CLurea; or KRU) data,
the 6538 included patients were more likely to be men and
non-Hispanic white; were more likely to have an arteriove-
nous ﬁstula as their vascular access; and had larger body mass
index, lower single–pool Kt/V (spKt/V), higher hemoglobin,
higher albumin, lower bicarbonate, and lower ferritin at base-
line (Supplemental Table 1). Additionally, compared with the
16,357 excluded patients who had CLurea data at baseline but
not at year 1, the included patients were more likely to be non-
Hispanic white; were more likely to have an arteriovenous
ﬁstula as their vascular access; and had greater RKF, higher
hemoglobin, and higher albumin at baseline. The mean6SD
age of the ﬁnal study cohort was 62614 years old, of which
65% were men, 56% were non-Hispanic white, 25% were
non-Hispanic black, and 68% were diabetic (Table 1). Their
median baseline renal CLurea was 3.4 (interquartile range
[IQR], 2.1–5.1) ml/min per 1.73 m2.
Predictors of Annual Decline in RKF
Renal CLurea rates at 1 year after initiation of hemodialysis were
lower than baseline levels (P for signed rank test ,0.001); me-
dian renal CLurea was 2.1 (IQR, 0.9–3.6) ml/min per 1.73 m
2,
and mean6SD annual change in renal CLurea was 21.16
2.8 ml/min per 1.73 m2. In the overall cohort, 1134 (17%),
1444 (22%), and 2073 (32%) patients had change in renal
CLurea ,23.0, 23.0 to ,21.5, and 21.5 to ,0.0 ml/min per
1.73 m2, respectively, and 1887 (29%) showed maintained or
increased CLurea during the ﬁrst year of dialysis (Table 1).
After adjustment for case mix characteristics and baseline
value, factors associated with less decline in renal CLurea in-
cluded non-Hispanic white; presence of atherosclerotic heart
disease; higher body mass index, hemoglobin, albumin, and
corrected calcium; and normalized protein catabolic rate
(nPCR) ,0.8 g/kg per day at baseline, whereas older age, di-
abetes, presence of congestive heart failure, and higher creat-
inine, phosphorus, intact parathyroid hormone (PTH), and
iron saturation at baseline were associated with faster decline
in renal CLurea (Table 2). Consistent ﬁndings were observed in
the fully adjusted model, whereas the association with faster
CLurea decline became signiﬁcant in women and higher serum
bicarbonate rates. In the sensitivity analyses, where patients
with baseline CLurea ,1.5 ml/min per 1.73 m
2 were excluded
(Supplemental Table 2), atherosclerotic heart disease was not
associatedwith annual change inCLurea. Additionally, nPCR and
intact PTH lost their signiﬁcance in the fully adjusted model.
RKF at 1 Year and Survival
A total of 1046 patients died during the follow-up period after
year 1 until the end of the study (December 31, 2011). There
wasa signiﬁcant trend toward lowermortalitywithhigher renal
CLurea (Ptrend,0.001 across all models). Compared with pa-
tients who had renal CLurea of 3.0 to,6.0 ml/min per 1.73 m
2
at 1 year after hemodialysis initiation, those who had renal
CLurea of 1.5 to ,3.0 and ,1.5 ml/min per 1.73 m
2 experi-
enced higher mortality, which remained signiﬁcant after ad-
justing for case mix characteristics (hazard ratio [HR], 1.26;
95% conﬁdence interval [95% CI], 1.08 to 1.47 and HR, 1.67;
95% CI, 1.44 to 1.94, respectively) or body mass index and
laboratory variables at 1 year after hemodialysis initiation
(Figure 1). The mortality risk in patients who had renal CLurea
of $6.0 ml/min per 1.73 m2 at year 1 was not signiﬁcantly
different in the unadjustedmodel and the casemix adjustment
model, but it was lower in the fully adjusted model (HR, 0.74;
95% CI, 0.57 to 0.97).
Annual Change in RKF and Survival
Cox regression analyses with restricted cubic spline functions
showed a signiﬁcant association of annual change in renal
CLurea with all-cause mortality in the minimally adjusted, case
mix–adjusted, and fully adjusted models (Figure 2); patients
with faster CLurea decline showed higher risks of mortality.
Case mix–adjusted HRs were 2.00 (95% CI, 1.55 to 2.59),
1.25 (95% CI, 1.16 to 1.35), 0.81 (95% CI, 0.73 to 0.91),
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and 0.61 (95% CI, 0.50 to 0.74) at26.0,23.0,60.0, and +3.0
ml/min per 1.73 m2 per year of change in CLurea, respectively
(reference: 21.5 ml/min per 1.73 m2 per year). These
associations were robust against additional adjustment for
baseline ultraﬁltration rate and its annual change. Consistent
trends were observed in subgroup analyses according to
Table 2. Association of baseline characteristics with annual change in residual renal CLurea among 6538 incident patients on
hemodialysis
Variables
Case Mix–Adjusted Model Fully Adjusted Model
b (95% CI) P Value b (95% CI) P Value
Baseline renal CLurea per 1.0 ml/min per 1.73 m
2 20.62 (20.65 to 20.59) ,0.001 20.70 (20.74 to 20.67) ,0.001
Age, yr
,50 20.11 (20.26 to 0.05) 0.17 0.17 (0.01 to 0.32) 0.04
50 to ,60 20.16 (20.29 to 20.02) 0.03 20.04 (20.18 to 0.10) 0.56
60 to ,70 Reference Reference
70 to ,80 20.08 (20.22 to 0.06) 0.25 20.19 (20.33 to 20.05) ,0.01
$80 20.29 (20.46 to 20.11) 0.001 20.48 (20.66 to 20.30) ,0.001
Men 20.01 (20.12 to 0.10) 0.90 0.26 (0.15 to 0.38) ,0.001
Race/ethnicity
Non-Hispanic white Reference Reference
Non-Hispanic black 20.34 (20.45 to 20.22) ,0.001 20.15 (20.28 to 20.02) 0.02
Hispanic and other 20.32 (20.44 to 20.19) ,0.001 20.10 (20.22 to 0.03) 0.14
Medicare as primary insurance 20.03 (20.13 to 0.07) 0.61 20.04 (20.14 to 0.05) 0.39
Central venous catheter use 0.09 (20.01 to 0.19) 0.06 0.19 (0.09 to 0.29) ,0.001
Comorbidities
Hypertension 20.03 (20.13 to 0.07) 0.53 20.01 (20.11 to 0.09) 0.86
Diabetes 20.16 (20.27 to 20.05) 0.004 20.20 (20.31 to 20.08) 0.001
Congestive heart failure 20.31 (20.41 to 20.21) ,0.001 20.27 (20.37 to 20.18) ,0.001
Atherosclerotic heart disease 0.18 (0.03 to 0.34) 0.02 0.19 (0.04 to 0.34) 0.01
Other cardiovascular disease 0.01 (20.13 to 0.16) 0.87 20.02 (20.16 to 0.12) 0.77
spKt/V per SD 0.01 (20.05 to 0.06) 0.79 0.01 (20.05 to 0.07) 0.79
Body mass index per SD 0.09 (0.04 to 0.15) 0.001 0.08 (0.02 to 0.14) ,0.01
nPCR, g/kg per d
,0.8 0.27 (0.12 to 0.43) ,0.001 0.19 (0.04 to 0.34) 0.01
0.8 to ,1.0 0.04 (20.09 to 0.18) 0.54 20.01 (20.14 to 0.12) 0.87
1.0 to ,1.2 Reference Reference
$1.2 20.04 (20.18 to 0.11) 0.64 0.02 (20.12 to 0.16) 0.76
Laboratories
Hemoglobin per SD 0.07 (0.02 to 0.12) ,0.01 0.05 (20.01 to 0.10) 0.09
Albumin, g/dl
,3.2 20.56 (20.70 to 20.41) ,0.001 20.73 (20.89 to 20.58) ,0.001
3.2 to ,3.6 20.28 (20.40 to 20.16) ,0.001 20.36 (20.48 to 20.24) ,0.001
3.6 to ,4.0 Reference Reference
$4.0 0.07 (0.03 to 0.12) 0.002 0.34 (0.20 to 0.48) ,0.001
Creatinine per SD 20.39 (20.45 to 20.33) ,0.001 20.38 (20.45 to 20.31) ,0.001
Calcium per SD 0.07 (0.03 to 0.12) 0.002 0.08 (0.03 to 0.13) 0.002
Phosphorus per SD 20.30 (20.35 to 20.25) ,0.001 220.17 (20.22 to 20.11) ,0.001
Intact PTH, pg/ml
,160 0.28 (0.12 to 0.44) 0.001 0.12 (20.04 to 0.28) 0.14
160 to ,320 0.23 (0.11 to 0.34) ,0.001 0.13 (0.01 to 0.24) 0.03
320 to ,640 Reference Reference
$640 20.25 (20.38 to 20.12) ,0.001 20.13 (20.26 to 0.00) 0.04
Iron saturation per SD 20.05 (20.10 to 0.00) 0.04 20.07 (20.12 to 20.02) ,0.01
Ferritin, ng/ml
,200 20.09 (20.23 to 0.04) 0.18 20.11 (20.24 to 0.03) 0.12
200 to ,400 20.05 (20.19 to 0.09) 0.49 20.05 (20.19 to 0.09) 0.46
400 to ,800 Reference Reference
$800 0.19 (20.08 to 0.45) 0.16 0.25 (20.01 to 0.51) 0.06
Bicarbonate per SD 0.01 (20.04 to 0.06) 0.60 20.13 (20.18 to 20.08) ,0.001
Case mix variables included baseline urine volume, age, sex, race/ethnicity, primary insurance, central venous catheter use, comorbidities, and spKt/V.
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baseline CLurea (Figure 3). Rapid CLurea decline (.3.0 ml/min
per 1.73 m2 per year) also showed a case mix–adjusted HR of
1.62 (95% CI, 1.27 to 2.07) for all-cause mortality. This asso-
ciation was not modiﬁed by baseline age ($65 or ,65 years
old), sex, race (white or nonwhite), diabetes, presence of con-
gestive heart failure, hemoglobin ($11.5 or ,11.5 g/dl), se-
rum albumin ($3.6 or ,3.6 g/dl), and serum phosphorus
($5.0 or ,5.0 mg/dl; Pinteraction.0.20 for all) (Figure 4).
Sensitivity Analyses Using Urine Volume as Another
Index of RKF
Median baseline urine volume was 900 (IQR, 550–1400) ml/d
(Supplemental Table 3). Median urine volume at year 1 was
650 (IQR, 380–1100) ml/d, and mean6SD annual change in
urine volume was 22406610 ml/d. Compared with factors
related to annual decline in CLurea, older age, non-Hispanic
black, diabetes, presence of congestive heart failure, lower
body mass index, lower serum albumin, higher serum creat-
inine, and higher serum phosphorus were consistently asso-
ciated with faster decline in urine volume, irrespective of the
adjustment model. Women, lower serum calcium, and higher
serumbicarbonate also showed signiﬁcant relationships to faster
annual decline in the fully adjusted model (Supplemental Table
4). These ﬁndings were conﬁrmed in the sensitivity analyses,
where patients with baseline urine volume,300 ml/d were ex-
cluded (Supplemental Table 5).
There was a signiﬁcant trend toward lower mortality at
higher urine volume (Ptrend,0.001 across all models) (Sup-
plemental Figure 1). Annual change in urine volume showed a
signiﬁcant association with all-cause mortality in all models,
Figure 2. Distributions and restricted cubic splines comparing the relationship of annual change in residual renal CLurea with all-cause
mortality among 6538 incident hemodialysis patients (2007–2010): (A) baseline renal CLurea adjustment model, (B) case mix adjustment
model, (C) fully adjusted model, and (D) additional adjustment for baseline ultraﬁltration rate (UFr) and its annual change on the fully
adjusted model. Annual changes in renal CLurea were calculated subtracting values at year 1 (the ﬁfth patient-quarter; the ﬁrst 91 days
of the second year of dialysis) from those at baseline (the ﬁrst patient-quarter; the ﬁrst 91 days of the ﬁrst year of dialysis). Dashed and
solid lines represent HR estimates and 95% CIs, respectively.
Figure 1. Renal CLurea and all-cause mortality risk in incident
hemodialysis patients. The mortality risk associated with renal
CLurea at 1 year after initiating dialysis among 6538 incident he-
modialysis patients (2007–2010) with three levels of adjustment.
There was a signiﬁcant trend toward lower mortality of higher
renal CLurea (P for trend ,0.001 across all models).
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including adjustment for ultraﬁltration rate and its annual
change (Supplemental Figure 2); patients with faster decline in
urine volume showed higher risk ofmortality. Consistent trends
were observed in subgroup analyses according to the baseline
urine volume categories shown (Supplemental Figure 3). Rapid
decline in urine volume (.600 ml/d per year) also showed
higher mortality risk in the case mix adjustment model, and
this association was not modiﬁed by any of the prespeciﬁed
variables (Pinteraction.0.20 for all) (Supplemental Figure 4).
DISCUSSION
Among 6538 incident hemodialysis patients who had available
urine data at the time of hemodialysis initiation and 1 year
afterward from a large dialysis organization in the United States,
greater renal CLurea rates at year 1 were associated with better
survival. Additionally, annual decline in renal CLurea showed a
gradient association with all-cause death. These associations
were robust against additional adjustment for laboratory vari-
ables and ultraﬁltration rate, and they were consistent across
strata of baseline RKF, age, sex, race, diabetes, congestive heart
failure history, hemoglobin, serum albumin, and serum phos-
phorus. Sensitivity analyses using urine volume as another index
of RKF yielded consistent associations.
Given the exclusion of RKF from the assessment of
hemodialysis adequacy in the recent End-Stage Renal Disease
Quality Incentive Program,18 the ﬁndings from our study are
both timely and relevant. At this time, the only metric consid-
ered in the ascertainment of hemodialysis adequacy is spKt/V,
with a threshold of$1.2. However, many patients early in their
course of ESRDmay retain substantial RKF, whichmay have an
important bearing on their achievement of adequate clearance
and volume removal, leading to better clinical outcomes. Fur-
thermore, individualizing hemodialysis prescriptions accord-
ing to RKF may allow for the reductions in dialysis treatment
time and frequency, which may favorably affect patients’ qual-
ity of life and reduce medical costs.19–21
Although several investigators addressed the importance of
RKFpreservation, even in patients onhemodialysis, evaluation
of change in RKF using at least two measurements separated
by a reasonably long time interval is needed to overcome lead
time bias. In a cohort study of 734 incident hemodialysis
patients from the United States conducted in the late 1990s,
RKF was qualitatively examined by questionnaire (urine
volume $250 or ,250 ml/d) in a prospective manner.10 Of
these patients, 260 (35%) responded at both baseline and 1
year, and patients who reported maintained urine volume
$250 ml/d during the ﬁrst 1 year of dialysis showed better
survival than those who lost urine output. The Netherlands
Cooperative Study on the Adequacy of Dialysis Study Group
prospectively examined 609 and 1191 patients new to perito-
neal dialysis and hemodialysis, respectively, and showed that
full loss of RKF was associated with higher mortality,
Figure 3. Distributions and case mix–adjusted all–cause death HRs of annual change in renal CLurea by using restricted cubic splines
among 6538 incident hemodialysis patients (2007–2010) stratiﬁed by baseline CLurea levels: (A) ,1.5 ml/min per 1.73 m
2, (B) 1.5
to ,3.0 ml/min per 1.73 m2, (C) 3.0 to ,6.0 ml/min per 1.73 m2, and (D) $6.0 ml/min per 1.73 m2. Annual changes in renal CLurea were
calculated subtracting values at year 1 (the ﬁfth patient-quarter; the ﬁrst 91 days of the second year of dialysis) from those at baseline
(the ﬁrst patient-quarter; the ﬁrst 91 days of the ﬁrst year of dialysis). Dashed and solid lines represent HR estimates and 95% CIs,
respectively.
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irrespective of modality, hemodialysis, or peritoneal dialysis.22
However, when RKFwas not fully lost, there was no signiﬁcant
association between RKF and mortality. Despite some discrep-
ancies in results, partly because of differences in study pop-
ulations, thresholds used to deﬁne RKF, and statistical modeling
approaches (traditional Cox models used to evaluate long-term
association in the former versus marginal structural model
used to evaluate short-term association and account for time-
dependent confounding in the latter), our study consistently
shows the survival beneﬁt of preserved RKF using a larger
national representative cohort of incident hemodialysis pa-
tients. Rapid decrease in RKF has also been identiﬁed as an
independent risk factor for all-cause death in patients on peri-
toneal dialysis.23
We observed large variations in annual change in RKF and
identiﬁed several predictors of preserved RKF at 1 year after
hemodialysis initiation after adjustment for baseline RKF
values and case mix characteristics. Compared with a previous
report by Moist et al.,9 women, nonwhite race, diabetes, and
history of congestive heart failure were consistent risk factors
of RKF decline. Although renin-angiotensin system inhibitors
have been suggested to preserve RKF in patients on hemodi-
alysis,9,24 medication information was not available in our
study. However, a recent randomized, controlled trial found
no signiﬁcant difference in RKF decline over time with use of
the angiotensin receptor blocker irbesartan versus placebo in
patients undergoing hemodialysis.25 Although the not remov-
ing water strategy with hemodialysis may maintain urine vol-
ume, it also increases BP, left ventricular mass index, and
cardiovascular events,26 suggesting the importance of individ-
ualized volume management to avoid both congestive heart
failure and intradialytic hypotension.9,27 Other potential strat-
egies include avoidance of nephrotoxic agents, ultrapure dial-
ysis ﬂuid,28 online hemodiaﬁltration,29,30 diuretic use,31,32
and incremental hemodialysis regimens.19–21,33–35
A substantial number of patients in this study increased
their renal CLurea rate during the ﬁrst 1 year of hemodialysis
treatment. Although it may be partly caused by measurement
error as with large decreases in RKF, subgroup analyses and
sensitivity analyses excluding subjects with low baseline RKF
yielded consistent results. Additionally, a US Renal Data Sys-
tem special study has shown that congestive heart failure and
AKI are among themost common reasons of hospitalization at
hemodialysis initiation,36 and approximately 5% of incident
hemodialysis patients recovered their kidney function with
successful discontinuation of dialysis treatment in 2008 and
2009.37 The prevalence of recovery of renal function is increas-
ing over time and may be underestimated if patients continue
dialysis without re-evaluation of RKF after recovery of their
renal function.
Weacknowledge several other limitations in this study.First,
cause-speciﬁc death was not available in this study. Second,
RKF measurement is not accurate given the use of CLurea and
not the average of renal urea and creatinine clearances and the
difﬁculties in complete collection of urine samples and its
punctuality in patient daily life. The use of factor 0.9 for pre-
dialysis serum urea nitrogen for renal CLurea calculationmight
have also induced errors to some extent. Nevertheless, the
population-level associations with clinical outcomes can be
estimated from an adequate number of subjects if such errors
are not associated with the outcome. Third, available RKF
measures may not be representative of those in the entire he-
modialysis population, because patients on dialysis with
limited or no RKF are less likely to have undergone urine col-
lections, especially at 1 year after hemodialysis initiation. This
potential selection bias might have resulted in missing patients
who lost RKF during the ﬁrst 1 year of dialysis, and thus, the
mortality risk of RKF decline might be underestimated. Addi-
tionally, although we adjusted for only baseline patient charac-
teristics and not those at year 1 to avoid overadjustment, RKF
decline could also be an intermediary between adverse events
(e.g., cardiovascular events and infection) during the ﬁrst year
of dialysis and subsequent mortality. Indeed, the mortality risk
of RKF decline was attenuated to some extent after adjusting
Figure 4. Overall and subgroup analyses of associations between
rapid decline in residual renal CLurea .3 ml/min per 1.73 m
2 per
year and all-cause mortality among 6538 incident hemodialysis
patients (2007–2010) in the case mix adjustment model. Annual
changes in renal CLurea were calculated subtracting values at year
1 (the ﬁfth patient-quarter; the ﬁrst 91 days of the second year of
dialysis) from those at baseline (the ﬁrst patient-quarter; the ﬁrst
91 days of the ﬁrst year of dialysis). Points and bars represent HR
estimates and 95% CIs, respectively. Alb, albumin; CHF, con-
gestive heart failure; Hgb, hemoglobin; Phos, phosphorus.
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for body mass index and laboratory variables at both baseline
and 1 year, but it still remained signiﬁcant (data not shown).
Although it is hard to estimate the net effect of the former and
the latter limitations, our results met seven of nine of the
criteria by Hill38 (i.e., temporal relationship, strength, dose-
response relationship, consistency, biologic plausibility, co-
herence, and reasoning by analogy), suggesting a possible
causal relationship between RKF decline and all-cause death
in patients on hemodialysis.
In conclusion, decline in RKF, both renal CLurea and urine
volume separately, shows a graded association with higher
mortality among incident hemodialysis patients. Future trials
are warranted to test the clinical beneﬁts of RKF preservation
strategies, including maintaining diuretic use and the incre-
mental hemodialysis regimen.
CONCISE METHODS
Patients
We retrospectively extracted, reﬁned, and examined data from all
incident hemodialysis patients who were ages $18 years old and re-
ceived hemodialysis treatment for $60 consecutive days in facilities
operated by a large dialysis organization (DaVita, Inc.) in the United
States from January 1, 2007 to December 31, 2010.39 Patients were
followed until December 31, 2011, and the follow-up time was di-
vided into patient-quarters (91-day periods from date of ﬁrst dialy-
sis). For each patient-quarter, patients were assigned the conventional
hemodialysis modality if they did not receive treatments other than
thrice weekly hemodialysis (i.e., peritoneal dialysis, less frequent in–
center hemodialysis, home hemodialysis, frequent in–center hemo-
dialysis, or nocturnal in–center hemodialysis) for at least 45 days
within the patient-quarter.
To examine RKF and the changes during the ﬁrst 1 year of
hemodialysis, we used all incident in–center hemodialysis patients
between 2007 and 2010 who were alive at year 1 and had measured
renal CLurea at the start of dialysis and year 1. First, we excluded pa-
tients who were censored or ever treated with peritoneal dialysis, noc-
turnal hemodialysis, or home hemodialysis during the ﬁrst 1 year of
dialysis. Second, we identiﬁed 22,895 incident hemodialysis patients
with baseline CLurea data from 67,311 patients whowere assigned only
conventional hemodialysis for the ﬁrst four patient-quarters. Among
them, 6538 patients also had RKF measurements at the ﬁfth patient-
quarter (i.e., the ﬁrst 91-day period of the second year of dialysis) and
were included in this study (details in Supplemental Figure 5). This
study was approved by the Institutional Review Committees of the
Los Angeles Biomedical Research Institute at Harbor–University of
California, Los Angeles; the University of California, Irvine Medical
Center; and the University of Washington.
Demographic, Clinical, and Laboratory Measures
The information on all-cause death, race/ethnicity, primary insur-
ance, access type, the presence of comorbidities, and laboratory
variables was obtained from the electronic database of the dialysis
provider. Tominimizemeasurement variability, all repeatedmeasures
for each patient during any given patient-quarter (91 days) were
averaged, and the quarterly means in each quarter were used in all
analyses. The averaged values during theﬁrst patient-quarter (theﬁrst
91 days of dialysis) served as baseline data.
Blood samples were drawn using uniform techniques in all dialysis
clinics and transported to the central laboratory (Deland, FL) typically
within 24 hours. All laboratory values were measured by automated
and standardized methods. Most laboratory values were measured
monthly, including serum urea nitrogen, creatinine, albumin, cal-
cium, phosphorus, and bicarbonate. Serum ferritin and intact PTH
were measured at least quarterly. Hemoglobin was measured at least
monthly in essentially all patients and weekly to biweekly in most
patients. Most blood samples were collected predialysis with the
exceptionof thepostdialysis urea,whichwasobtained to calculateurea
kinetics.
The average serum urea concentrations during the collectionwere
assumed to be 90% of the predialysis concentrations according to the
approach by Daugirdas et al.,40 and thus, renal CLurea was calculated
as follows:
renal CLurea ðml=minÞ ¼
urinary urea nitrogen ðmg=dlÞ3urinary volume ðmlÞ
collected time ðminÞ3½0:93serum urea nitrogen ðmg=dlÞ;
where serum urea nitrogen was obtained on the closest day within6
28 days to urine collection. Observations with CLurea.15 ml/min or
urine volume .3000 ml/d were excluded from this study. Among
the eligible 23,111 CLurea observations, urine collected time was
reported as 1440 minutes in 22,716 observations (98%), ranging
from 720 to 2880 minutes. Serum urea nitrogen was measured on
the same day of urine collection in 22,520 (97%) patients. The
differences between our calculated CLurea and CLurea reported from
the large dialysis organization were within 60.01 ml/min in 22,445
observations (97%) (Supplemental Figure 6). Renal CLurea was then
adjusted for body surface area and expressed as milliliters per minute
per 1.73 m2.1,41 Annual changes in renal CLurea and urine volume
were calculated by subtracting values at year 1 (the ﬁfth patient-
quarter; the ﬁrst 91 days of the second year of dialysis) from those at
baseline (the ﬁrst patient-quarter; the ﬁrst 91 days of the ﬁrst year of
dialysis). spKt/V delivered by dialysis was calculated using urea ki-
netic modeling equations.42 nPCR was calculated taking renal CLurea
into account.43
Statistical Analyses
Renal CLurea was used as the index of RKF in the primary analyses,
and urine volume was used in the sensitivity analyses. Differences in
baseline characteristics between included versus excluded patients
were compared by standardized differences because of the relatively
large sample size of this study.44,45 Patients were categorized into four
groups according to annual change in renal CLurea (,23.0, 23.0 to
,21.5,21.5 to,0.0, and$0 ml/min per 1.73 m2) or urine volume
(,2600, 2600 to ,2300, 2300 to ,0.0, and $0 ml/d), and the
association with each patient characteristic was evaluated by non-
parametric trend test. Linear regression with roust estimation was
used to identify the predictors of annual change in RKF. Survival
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analysis with Cox regression was used to estimate association be-
tween the exposure variable (i.e., RKF at year 1 or annual change
in RKF) and all-cause mortality. Annual changes in RKF (i.e., CLurea
and urine volume) were modeled as continuous variables, and their
relationship with all-cause deathwas estimated using restricted cubic
spline functions with four knots at the 5th, 35th, 65th, and 95th
percentiles of each index. In the primary analyses, 21.5 ml/min
per 1.73 m2 and 2300 ml/d were used as references for changes in
CLurea and urine volume, respectively. Median values were used as
references in each subgroup analysis. The ﬁrst day of the ﬁfth patient-
quarter (i.e., 364th day of dialysis treatment) was used as the entry
day of each patient. Proportional hazards assumptions were tested
using log-log against survival plots and Schoenfeld residuals.
Models were examined with three levels of adjustment as listed
below.
1. Unadjusted model or minimally adjusted model that included
baseline RKF values.
2. Case mix–adjusted models that included the above plus age, sex,
race, ethnicity (non-Hispanic black, non-Hispanic white, Hispanic,
or other race/ethnicity), primary insurance (Medicare and others),
central venous catheter use, and six comorbidities (hypertension,
diabetes, presence of congestive heart failure, atherosclerotic heart
disease, other cardiovascular disease, and spKt/V).
3. Fully adjusted models that included all of the covariates in the case
mix model plus body mass index, nPCR, and nine laboratory var-
iables (hemoglobin, serum albumin, creatinine, albumin-corrected
calcium, phosphorus, iron saturation, total bicarbonate, and natural
log–transformed intact PTH and ferritin).
When evaluating the association of RKF indices at 1 year after
hemodialysis initiation with mortality, we used primary insurance,
vascular access type, and laboratory variables obtained from the same
period (i.e., the ﬁfth patient-quarter). For analyses of the association
between annual changes in RKF indices and all-cause mortality,
baseline variables were used to avoid overadjustment, because those
variables at year 1 may have been inﬂuenced by change in RKF (i.e.,
intermediaries between RKF decline and all-cause death). Additional
adjustment for ultraﬁltration rate at baseline and its annual change
was conducted on the fully adjusted model to unfold how ﬂuid re-
moval may affect the RKF-mortality association.
Linear assumption among covariates was examined by using
restricted spline functions and a likelihood ratio test for goodness of
ﬁt.46 For linear regression analyses where annual change in RKF was
used an outcome, age, nPCR, and serum concentrations of albumin,
intact PTH, and ferritin retained one or more spline functions (i.e.,
nonlinear association) and thus, were categorized irrespective of
models as follows: ﬁve groups of age (,50, 50 to ,60, 60 to ,70,
70 to,80, and$80 years old), four groups of serum albumin (,3.2,
3.2 to,3.6, 3.6 to,4.0, and$4.0 g/dl), ﬁve groups of serum calcium
(,8.5, 8.5 to,9.0, 9.0 to,9.5, 9.5 to,10.0, and$10.0 mg/dl), four
groups of intact PTH (,160, 160 to ,320, 320 to ,640, and $640
pg/ml), and four groups of serum ferritin (,200, 200 to,400, 400 to
,800, and $800 ng/ml). In the Cox regression analyses, signiﬁcant
spline functions were kept instead of categorizing variables and used
in the multivariate models.
Effectmodiﬁcation of the association between annual RKF decline
(i.e., .3.0 ml/min per 1.73 m2 in CLurea or .600 ml/d in urine
volume) and all-cause death by baseline age ($65 or ,65 years
old), sex, race (white or nonwhite), diabetes, presence of congestive
heart failure, hemoglobin ($11.5 or ,11.5 g/dl), serum albumin
($3.6 or ,3.6 g/dl), and serum phosphorus ($5.0 or ,5.0 mg/dl)
were examined by including each interaction term into case mix
adjustment models. The frequency of missing data was low (,1%
for most laboratory tests, except for nPCR [4%] and creatinine
[4%]), and the multiple imputation method with ﬁve datasets was
used in all regression analyses. Analyses were conducted using STATA
MP, version 13.1 (StataCorp, College Station, TX) and SAS, version
9.4 (SAS Institute Inc., Cary, NC).
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